Core Viewpoint - Mingyu Pharmaceutical Co., Ltd. has submitted its prospectus to the Hong Kong Stock Exchange, indicating its transition towards commercialization with a robust clinical-stage oncology product portfolio and a new PD-1/VEGF bispecific antibody [2]. Group 1: Company Overview - Mingyu Pharmaceutical was established in 2018 and is nearing commercialization as a biotechnology innovation company [2]. - The company has a dual growth engine consisting of proprietary antibody-drug conjugate (ADC) platforms and a new PD-1/VEGF bispecific antibody [2]. Group 2: Financial Performance - The company has not yet commercialized any candidate drugs but expects to generate revenue of RMB 264.15 million in the first half of 2025 through a licensing agreement with Qilu [2]. - Projected losses for the years 2023, 2024, and the first half of 2025 are RMB 137.275 million, RMB 282.631 million, and RMB 167.008 million respectively [3][4]. - Revenue and costs for the fiscal year ending December 31, 2023, and the first half of 2025 are detailed, with a gross profit of RMB 263.802 million expected in 2025 [4]. Group 3: Leadership - Dr. Cao Guoqing, the Chairman and CEO, has over 30 years of experience in innovative drug research and management, having held significant positions in various pharmaceutical companies [6]. - The CFO, Zhong Zhongren, has over 16 years of experience in auditing and financial management, previously working in notable firms such as Deloitte and various pharmaceutical companies [8].
明宇制药38岁CFO钟仲人与董事长为复旦校友，曾任阅文集团财务总监